Contact
Thank you for contacting us.
Someone from our office will be in touch with you soon.
If you would like to discuss eligibility for a specific research study with someone on the phone, please reach out to us at 561-296-3850.
If you’d like to learn more about the topics of Alzheimer’s disease, migraines, Multiple Sclerosis and other neurological disorders, please take some time to read our blog articles below.
A Link Between Inadequate Sleep and Increased Alzheimer’s Risk?
Insufficient or poor-quality sleep may increase the risk of developing Alzheimer’s disease, according to a health advisory from the American Academy of Sleep Medicine (AASM). Their advisory is based on the results of epidemiological studies that have shown a possible...
Anti-CGRP Migraine Drug Shows Promising Symptom Relief
A new small molecule calcitonin gene-related peptide (CGRP) drug in phase 3 clinical trials has shown promising relief of migraine symptoms when administered as an acute single-dose treatment. The migraine drug, Rimegepant, relieved pain and other bothersome migraine...
The Impact of Migraine at Work
A large global survey of migraine patients which included over 11,000 respondents from 31 countries found that many migraine sufferers commonly deal with functional impairments at work due to their symptoms. Respondents of the survey had at least four migraine days...
Cognitive Benefits of Exercise Confirmed by Meta-analysis
New findings from a meta-analysis of studies involving over 11,000 individuals has strengthened the connection between physical exercise and benefits to cognition. Published in the journal Neurology Clinical Practice, this meta-analysis revealed improvements in...
Depression and Memory Loss in Older Adults
Depression in older adults may be correlated with memory loss due to accelerated brain aging, according to the findings of a study published earlier this year in the journal Neurology. Based on the results of the study, which involved older adult subjects (mean age of...
Erenumab (Aimovig) FDA Approved as First Anti-CGRP Migraine Drug
Adults with migraine now have an additional preventative treatment option available to them, thanks to a new and unique migraine medication that has been approved by the Food and Drug Administration (FDA). Aimovig (erenumab-aooe) is a novel, first of its kind...
Current Migraine Prevention Strategies
Today, there are a variety of different migraine prevention options which can help ease the lifestyle burdens that migraine sufferers often live with. There are several goals to migraine prevention, such as a lessening of functional impairments and disability,...
Subthreshold Amyloid Growth Associated with Memory Decline
A recent study examined whether beta-amyloid growth in cognitively normal older adults who are considered beta-amyloid negative (as opposed to beta-amyloid positive) experience symptoms of cognitive decline. Beta-amyloid is the protein component that forms the amyloid...
New Blood Test Predicts Mild TBI Brain Bleeds
The FDA has recently approved the first blood test that indicates the presence of bleeding in the brain from mild traumatic brain injury (TBI). This new test is intended to identify certain patients who do not need imaging to determine whether they have intracranial...
Migraine Facts and Statistics
Migraine is a neurological disease that affects approximately one billion people worldwide. In fact, according to the Migraine Research Foundation, it is the third most prevalent disease in the world. To give you an idea of how common and impactful migraine is in the...
Our Doctors
To view a brief description of the specialties and background of each of our physicians click on their name.